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Abstract
Background: Nationally-representative surveys suggest that females have a higher prevalence of HIV than males in
most African countries. Unfortunately, these results are made on the basis of surveys with non-ignorable missing data.
This study evaluates the impact that differential survey nonresponse rates between males and females can have on
the point estimate of the HIV prevalence ratio of these two classifiers.
Methods: We study 29 Demographic and Health Surveys (DHS) from 2001 to 2010. Instead of employing often used
multiple imputation models with a Missing at Random assumption that may not hold in this setting, we assess the
effect of ignoring the information contained in the missing HIV information for males and females through three proposed statistical measures. These measures can be used in settings where the interest is comparing the prevalence of
a disease between two groups. The proposed measures do not utilize parametric models and can be implemented by
researchers of any level. They are: (1) an upper bound on the potential bias of the usual practise of using reported HIV
prevalence estimates that ignore subjects who have missing HIV outcomes. (2) Plausible range intervals to account for
nonresponses, without any additional parametric modeling assumptions. (3) Prevalence ratio inflation factors to correct the point estimate of the HIV prevalence ratio, if estimates of nonresponders’ HIV prevalences were known.
Results: In 86% of countries, males have higher upper bounds of HIV prevalence than females, this is consonant with
males possibly having higher infection rates than females. Additionally, 74% of surveys have a plausible range that
crosses 1.0, suggesting a plausible equivalence between male and female HIV prevalences.
Conclusions: It is quite reasonable to conclude that there is so much DHS nonresponse in evaluating the HIV status
question, that existing data is plausibly generated by the situation where the virus is equally distributed between the
sexes.
Keywords: HIV reporting, HIV testing, Missing at random, Nonresponse, Survey bias
Background
The use of large-scale surveys to estimate local and
national prevalence of disease, or other population characteristics, typically encounter nonresponse on the status of the disease [19]. If the aim of a study is to make
comparisons of disease prevalence between two groups,
nonresponse in survey items may introduce bias in the
comparison, especially if the non-response rate differs
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in the two groups. A variety of methods are available to
address nonresponse including weighting adjustments to
account for total nonresponse and imputation methods
to assign values to missing response items [4]. The development of these suite of methods are important because
accurate national prevalence estimates are needed for
monitoring the pandemic, policy formulation, planning
and evaluating treatment interventions.
Consider the motivating example of estimating HIV
prevalence in African countries. Early published estimates of HIV prevalence for African countries were
derived from sentinel surveillance which have shown to
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over—and under—estimate the prevalences when measured this way [2, 13, 14, 18]. This limitation has led to the
estimation of HIV prevalence through, presumably more
accurate, national population-based surveys [27].
The largest national population-based surveys designed
to estimate HIV prevalence in the developing world are
the Demographic and Health Surveys (DHS). The DHS
aim to be a nationally representative, population-based
set of surveys including HIV prevalence data for multiple countries of Africa, in part because of its use of blood
collected for HIV testing [5, 9]. One of the claimed major
advantages of a DHS is that it provides researchers the
ability to estimate HIV prevalence for the general population and for certain subgroups, such as sex and age
groups.
Throughout Africa, empirical evidence suggests that
despite large HIV prevalence differences between countries, females consistently have higher HIV prevalence
than males [1, 11, 15, 21, 29, 30, 40]. Theories have been
advanced to explain that the observed sex difference of
HIV prevalence in Africa is driven by multiple factors
[25]. Biological differences between males and females
are thought to explain the sex difference in HIV prevalence [10, 31, 32]. It has been observed that younger
females tend to have older male sexual partners who
are at higher risk of HIV [16, 17]. Biologically, it is also
believed that there is higher efficiency of transmission
from males to females than vice versa [28]. It has also
been reported that socially, females in African countries
have less authority in controlling the dynamics of sexual
behavior [3, 36]. That such a sex differential exists is not
surprising given the sex differences in the perception of
health services that have existed [35, 39].
The aim of our study is to evaluate the role of yet
another factor in the posited observed differences,
namely nonresponse (refusal to consent to being tested),
as a potential explanation that could modify the observed
sex differences in HIV prevalence estimates in 29 DHSs
from 2001 to 2010. It is common for population-based
surveys to experience non-ignorable nonresponse on HIV
relevant variables due to refusal to provide a blood sample for HIV testing, subject absenteeism, subject mobility
and general non-consent. Depending on actual reasons
why subjects fail to provide HIV testing information, survey nonresponse in the numbers experienced in the DHS,
cannot be ignored because of the potential to bias estimates of HIV prevalence. We hypothesize that the differential nonresponse rates between males and females
can play a sizable role in the supposed differences of HIV
prevalence; certainly when the basis for such claimed sex
differences are the DHS. Several methods to account for
nonresponse have been proposed including weighting
adjustments [26], Heckman-type selection models [6],
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mathematical modeling [33] and multiple imputation
[27]. The most common approach to address this differential nonresponse issue is to perform multiple imputations on the missing data [11, 29, 30, 42]. These studies
conclude that missing subjects typically have higher HIV
prevalence but the overall effect of nonresponse is negligible and the observed female to male HIV prevalence
ratio changes minimally. The biggest limitation of using
multiple imputation in this setting is that these studies make a ‘Missing at Random’ (MAR) assumption [23]
that implies that the HIV status of nonresponders is the
same as responders with the same observed covariates.
However, if an unobserved covariate is correlated with
the decision to get tested and HIV status, this condition
is violated and multiple imputation would not be a suitable method to address this nonresponse issue. In this
HIV example, this is likely to be the case as individuals
who suspect or know that they are HIV positive may not
adhere to being tested. HIV remains a highly stigmatizing disease in many African countries and subjects may
decide not to participate in the survey because of a fear
of discovering their status, or having their status possibly
revealed and not seeing any advantage in participating in
the survey [41]. This issue is compounded when the prevalence of HIV testing is substantially different between
males and females [34].
As a companion to multiple imputation when it is not
appropriate to assume response is MAR, we discuss three
statistics that are straightforward and intuitive to perform to study the sensitivity of inference when there is
no single accepted class of assumptions about the nonresponse mechanism. First, we present an upper bound
on the potential bias of sex-specific HIV prevalence
estimates when using only the response data and show
that this upper bound depends on the amount of nonresponse in males and females. Second, we introduce the
concept of plausible range to this argument, which studies the effect of nonresponse on the estimate of the sex
HIV prevalence ratio without any additional modeling
assumptions. Finally, we derive an HIV prevalence ratio
inflation factor that would correct the estimate of the
HIV prevalence ratio if the nonresponders HIV prevalence were known.

Methods
Study population and data

The standard DHSs include information about house
member demographic characteristics including age and
sex. Since 2001, a subset of DHSs have included HIV testing results to produce supposed nationally representative
estimates of HIV prevalence. We study the (first) 29 DHS
available to us as of writing this paper that performed
HIV-related measurements.
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We evaluate the sex-specific characteristics of the
national surveys including the number eligible for HIV
testing, the HIV testing response rate, the age range, the
HIV prevalence estimate and the ratio of female to male
HIV prevalence. HIV prevalence is defined as the number of subjects with a positive test result for HIV-1 or
HIV-2 over the number tested for HIV. HIV response
rate was taken to be the number of subjects with an HIV
test result over the number eligible for HIV testing. We
define nonresponse as being eligible for HIV testing and
having a missing observation on HIV testing which could
have been due to refusal to be tested, not being available
during the interview, or any other factor. Our analyses
apply individual HIV sampling weights that account for
the DHS sample design [38].
Statistical analysis

To evaluate the impact of missing HIV outcomes on the
HIV prevalence estimates we present three informative
quantities, none of which requires any further modeling
assumptions to be valid. The first measure we present is
the upper bound on nonresponse bias. Following a similar framework to that proposed by Cochran [7], let p
denote the true HIV prevalence for a country. Denote by
w the proportion of nonresponders in a survey. Associated with the nonresponders is their HIV prevalence that
we label pnr. The HIV prevalence of the population, p,
can be expressed by the following composition formula:

p = pnr w + pr (1 − w)

(1)

where pr is the prevalence of HIV for the subjects who
consented to HIV testing (i.e. responders).
Equation (1) identifies how the proportion of the nonresponders in the population plays a role in the estimation of national HIV prevalence. Using this formula, we
can calculate the bias induced by using the HIV prevalence of the fully observed subjects as the true HIV prevalence. We have that the bias,


Bias = wpnr − pr .

depends on the amount of nonresponse (w) and the difference in HIV prevalence between the population that
responds and those who do not respond to the survey.
Furthermore, because the term |pnr − pr | is between zero
and one, w provides an upper bound on the bias,

Bias ≤ w

(2)

that makes it evident that the difference between the true
HIV prevalence and the prevalence of the fully-observed
subjects will be at most the proportion of nonresponses
in the population. Given that pr is known, a sharper
bound for the bias is simply



Bias ≤ w 1 − pr

(3)

PR = (PR− , PR+ )

(4)

when it is assumed that the prevalence of nonresponders
is larger than that of responders (i.e. pnr > pr).
The second quantity we present is the plausible range.
Instead of addressing the nonresponse issue through
scientifically questionable MAR imputation models, we
propose to focus on the effect this issue has by implementing the metric of plausible range to more honestly
evaluate the information in the survey. Inspired by the
work of Cochran et al. [8] we first look at the estimated
prevalence if we assume all missings were to test negative. Then the estimated prevalence if all missings were
to test positive. We construct the HIV prevalence ratio
plausible range comparing females to males as:
where PR− denotes the estimated HIV prevalence ratio
when all the missing HIV responses for males and females
are assigned a negative test result and PR+ denotes the
estimated HIV prevalence ratio when all nonresponders
are assigned a positive HIV test result. Formulations for
PR− and PR+ can be found in the Appendix. The plausible range interval is a measure of how missing HIV
outcomes potentially affect the point estimate of the sex
HIV prevalence ratio. A narrow plausible range suggests
that the effect of nonresponse on the point estimate of
the prevalence ratio is minimal. Additionally, the location
of the plausible range interval is important. If the plausible range interval crosses the null value of 1.0, it is plausible that the HIV prevalence for females is equivalent
to the HIV prevalence for males even before taking into
account the standard error of the prevalence ratio. We
present this statistic as a conservative guide and not as
a worst-case scenario. Of course the worst-case scenario
would have all male missings be in the one direction and
all the female missings be in the other direction, but we
do not consider this possibility, preferring to believe that
the reasons for missingness are more likely to be similar
between the sexes than completely opposite.
The next measure, the prevalence ratio inflation factor, allows us to quantitate differential sex-behavior. We
explore the joint role that nonresponse rates and nonresponders HIV prevalence plays on the estimate of
the sex prevalence ratio. After some algebra (shown in
the Appendix), the true HIV prevalence ratio between
females and males (RRadj) adjusting for the HIV characteristics of nonresponders can be expressed as


1 + wF (RF − 1)
RRadj = RRobs ×
(5)
1 + wM (RM − 1)
where RRobs is the observed HIV prevalence ratio
between females and males, wF is the proportion of
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female nonresponders, RF is the ratio of HIV prevalences
of nonresponders to responders for the female population, wM is the proportion of male nonresponders, and
RM is the ratio of HIV prevalences of nonresponders
to responders for the male population. The bracketed
term on the right side Eq. (5) is what we term the prevalence ratio inflation factor, which depends on male and
female nonresponse rates (available from the survey) and
the HIV prevalence ratio between nonresponders and
responders (which is unavailable from the survey because
the HIV prevalence of nonresponders is unknown). If a
reliable estimate of the HIV prevalence for female and
male nonresponders could be obtained, then it would
be possible to adjust the observed prevalence ratio to
obtain a more representative female to male HIV prevalence ratio that accounts for missing HIV outcomes using
Eq. (5).

Results
Sex-specific observed HIV prevalence estimates and
nonresponse rates for each of the 29 DHS are presented
in Table 1. We see a clear pattern of higher reported HIV
prevalence among females when compared to males. Of
the 29 DHS analyzed, 26 had an HIV female:male prevalence ratio greater than one. The three highest reported
HIV prevalence ratios among the surveys were in Cote
d’Ivoire, Senegal and Ethiopia. In these three countries
the HIV response rates for males (that is, males who
consented to being tested) were considerably lower than
most DHS. Across all the DHS analyzed, males had a
higher HIV nonresponse rate compared to females except
for the Congo Brazzaville survey. The average HIV testing nonresponse rate across all surveys for females was
13.4% (range 2.7–29.6%; median: 12.3%) and for males
20.2% (range: 4.4–36.7%; median: 20.1%).
Upper bound on nonresponse bias

In order to avoid having the older male age groups influence the results, we restrict the sample to subjects in
the 15–49 age range. We show bar plots in Fig. 1 of the
reported HIV prevalence for males and females and their
HIV prevalence upper bound using Eq. (3) for 29 DHS
country surveys. From Fig. 1 we observe that the upper
bound on the HIV prevalence estimate is dependent
on the nonresponse rate. As expected, countries with
high nonresponse rates have a larger upper bound and,
importantly, this size varies between males and females.
The bar plots from Fig. 1 identify 25 out of 29 countries
that have a higher HIV prevalence upper bound for males
than females, suggesting that it is possible that the HIV
prevalence ratio can be less than one, reversing the direction of the observed sex gap in HIV prevalence.
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Countries with low observed HIV prevalence estimates typically have higher male HIV upper bounds
than females. In some instances, the upper bounds on
HIV prevalence are twice the size for males compared
to females. For example, Senegal has an observed HIV
prevalence ratio of 2.07 suggesting that females are twice
as likely to test HIV positive compared to males. If the
upper bounds are achieved for males and females in the
Senegal survey, this would result in an HIV prevalence
ratio of 0.66, making females 33% less likely to test positive for HIV than males. Of course, a whole range of ratio
values between those two extremes is plausible.
We also explore how the HIV prevalence and its upper
bound vary for males and females across different age
subgroups. For the 29 DHSs studied, we group country
surveys into four categories, depending on their HIV
testing response rates. Within each category, we take the
weighted average of HIV prevalence and upper bound
by age group. We plot the weighted average of observed
HIV prevalence and upper bound across age groups in
Fig. 2. We see that for surveys with low response rate,
the observed difference between female and male HIV
prevalence is large. For surveys with higher response rate
(> 85%, for example), the observed HIV prevalence difference is smaller across age groups. Additionally, the upper
bound of HIV prevalence is consistently higher across
all age groups in each of the four survey response categories. A telling finding is that as HIV testing response
rates increase, the upper bounds for males and females
HIV prevalences converge (i.e. are equivalent across all
age groups).
Plausible range

Figure 3 plots the plausible range for 27 DHS (two surveys were excluded because individual sampling weights
could not be reliably used for nonresponders). From
Fig. 3, we note that 20 of the 27 surveys (74%) had a
plausible range that crossed the value of 1.0. With the
exception of Sao Tome and Principe, the plausible range
intervals that did not cross the null value had intervals
that were above 1.0 (Cameroon, Congo Brazzaville, Cote
d’Ivoire, Lesotho 2009, Rwanda and Swaziland). We also
note that for every DHS except the Mozambique and
Rwanda surveys, the point estimate of the HIV prevalence ratio is skewed to the right of the plausible range
interval. This suggests that the prevalence ratio is more
sensitive to nonresponder’s positive HIV test results. The
point estimate of HIV prevalence ratio is likely to tend to
the null if we believe that the nonresponders are mostly
HIV positive individuals.
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Fig. 1 Bar plots of female and male observed HIV prevalence and the upper bound of the HIV prevalence for each of the 29 DHS. Dark red denotes
observed female HIV prevalence while light red denotes the female HIV prevalence upper bound. Dark blue denotes observed male HIV prevalence
while light blue denotes the male HIV prevalence upper bound. Note Letters define the country and if the country had more than one DHS, the last
digit of the survey year is added at the end of the country letters. The upper bound used in these estimations are derived from Eq. (3)

Prevalence ratio inflation factor

An important factor in the estimation of the HIV prevalence ratio is the HIV prevalence of female and male
nonresponders. Equation (5) can be used to obtain an
estimate of the true HIV prevalence ratio that accounts
for sex-specific nonresponse rates and nonresponders
HIV prevalence. For example, the reported HIV prevalence in Zimbabwe for females was 21.1% and for males
14.6%. The reported HIV prevalence ratio is thus 1.45
suggesting that females are 45% more likely to have HIV

than males in 2005–2006. The response rate for females
(75.9%) was higher than males (63.6%). If the HIV prevalence for the 24.1% of females who did not respond and
the 36.4% of males who did not respond could be estimated, then we could use Eq. (5) to obtain an adjusted
HIV prevalence ratio. For the sake of illustration, suppose that the HIV prevalence of nonresponders could be
estimated and is 25.0% for both males and females. Using
this information and Eq. (5), we obtain an adjusted HIV
prevalence ratio:
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RRadj
RRadj
RRadj


1 + wF (RF − 1)
= RRobs ×
1 + wM (RM − 1)


1 + 0.241 (1.18 − 1)
= 1.45 ×
1 + 0.364(1.72 − 1)
= 1.20


The Zimbabwe HIV prevalence ratio changes from 1.45
to 1.20. This exercise illustrates the importance of obtaining reliable estimates of the subjects who do not consent
to HIV testing. Unfortunately, we do not know the true
HIV prevalence of the nonresponders, but we can use
Eq. (5) to assess how the HIV prevalence ratio changes

for different nonresponse HIV prevalences between
males and females.

Discussion
While biological and social factors continue to play a
role in the observed difference between male and female
HIV prevalence in Africa, survey nonresponders has an
adverse effect on the validity of the inference one can
draw from such surveys. One can make assumptions,
usually unverifiable ones, in order to use statistical models to impute the information. When those assumptions
are questionable, it is important to consider studying the
sensitivity of inference to various models for nonresponse
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Fig. 3 Plausible range plot for the HIV prevalence female to male prevalence ratio for 27 DHS. Note The left endpoint of the interval is the plausible
value of the prevalence ratio if all nonresponders tested positive. The right endpoint of the interval is the plausible prevalence ratio value if all
nonresponders tested negative. The solid square symbol is the observed prevalence ratio for the particular survey. These intervals only display some
of the consequences of the missing data. They do not display the sampling uncertainty

that do not adopt the Missing at Random assumption. In
the studies that report the gender difference in HIV prevalence [11, 30, 42], sensitivity approaches to the MAR
assumption such as pattern-mixture models [22] are not
being reported perhaps because they are complex and
hard to justify in practice. Alternatively, one can evaluate
the impact the missing information has on the inference.
We have chosen the latter, namely to evaluate the impact
the missing information has on 29 DHSs, focusing on
the sex-ratio of HIV infected individuals. Our findings
strongly suggest that the data in these surveys should
not be the basis for the common belief that the HIV pandemic in Africa disproportionately affects females. It is
quite reasonable to conclude that there is so much nonresponse, that existing data is plausibly generated by the

situation where the virus is equally distributed between
the sexes.
In general, multiple imputation methods stress the
importance of studying the sensitivity of inferences to
various models for nonresponse [37]. Many of the studies looking at the difference in HIV prevalence between
males and females fail to perform sensitivity analyses
looking at multiple imputations assuming Missing Not
at Random (MNAR). In practice, many researchers find
the methods to perform sensitivity analyses using MNAR
multiple imputation (e.g. pattern-mixture modeling) to
be complex. We have provided an additional approach
that can be implemented by researchers of any level.
The plausible range we present gives an indication of
how the point estimate of the prevalence ratio changes
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when assigning subjects with an unobservable HIV outcome to be all positive or all negative. This exercise indicates how much information there is in the data, and how
robust our conclusions are to the data that are missing.
Overall, the point estimate of the HIV prevalence ratio
is skewed to the end of the plausible interval that assigns
all subjects to be HIV positive, suggesting that the HIV
prevalence ratio has more flexibility to decrease towards
the null than to increase away from the null when
accounting for nonresponders’ HIV status. This interval
can also be used to evaluate the possibility of the point
estimate of HIV ratio to be close to or equal to 1.0. About
three-quarters of DHS surveys had a plausible range that
crosses 1.0, suggesting a plausible equivalence between
male and female HIV prevalences for most countries.
Even among surveys where both males and females
had a high response rate (> 88%), we observed that half
of those surveys had a plausible range that crossed 1.0.
Furthermore, if one were to incorporate the information
that these numbers result from surveys that are subject to
sampling variability, wider intervals would result. While
not all countries show evidence that female and male HIV
prevalence is equivalent, this exercise shows the variability of this possibility across surveys. Lastly, the construction of the plausible range intervals produce intervals that
are wider than one would encounter given these largescale studies but tighter bounds would require a fabrication of questionable and tenuous assumptions. Further,
if we include sampling variability in calculating any sort
of bounds, such as confidence intervals, for example, we
would end up with even wider bounds.
Another statistical measure that we present to address
nonresponse is the prevalence ratio inflation factor.
This allows an estimate of the HIV prevalence ratio that
adjusts for differences in HIV prevalence between male
and female nonresponders to be calculated. Unfortunately, we do not have information on HIV status of
nonresponders, so it is difficult to know how this group
behaves, but this ratio can be studied to see the potential
for change. There have been some studies that show that
nonresponders behave differently from responders [24].
It might be interesting to identify factors that contrast
the nonresponders from the responders [12] and methods to estimate the HIV prevalence of nonresponders
[20] to complete the story. Additional limitations which
could be addressed by future work include: incorporating the reason for refusal to provide a blood sample for
HIV testing and extending these methods to evaluate the
impact of differential nonresponse on the standard error
of the point estimate.
Future studies could expand on the plausible range
interval by considering different endpoints that are not
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all negative test results and not all positive HIV test
results. For example, one can consider a scenario where
75% of males and females had an HIV positive test result
from which new plausible range intervals could be constructed. Placing a distribution(s) on this unknown
parameter would yield credible intervals for the parameters of interest. Also, our proposed statistics only evaluated nonresponse for subjects that agreed to interview
but did not agree to HIV testing. The three proposed statistics can be applied to the scenario where subjects do
not agree to interview at all. Lastly, future studies should
evaluate the robustness of the three measures using simulated data.

Conclusions
Methods described in this paper evaluate the reported
sex difference in HIV prevalence from 29 DHSs, without
the probably unwarranted assumption of “data missing at
random” to create data not gathered. Our analyses demonstrate the large impact that existing differential HIV
testing nonresponse between males and females can play
on HIV prevalences and especially on sex driven prevalence ratios in Africa. Indeed, it is of such magnitude that
one can make a plausibly, qualitatively different conclusion from the data than has been made in the past, when
the missing data was ignored, or equally as misleading,
modeled using untenable assumptions.
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Appendix
We define the plausible range to be PR = (PR− , PR+ ),
where PR− is the prevalence ratio between females and
males when all missing observations are assigned a negative HIV status. If we define the prevalence of the population when all female nonresponders have a negative HIV
F , then we can show
outcome as p−
F
p−
= prF (1 − wF )
F is zero. A similar derivation can be produced
because pnr
M
for p− (the HIV prevalence when all male nonresponders
are designated a negative HIV test result). The PR− then
becomes

PR− =

F
p−
pF (1 − wF )
= Mr
M
pr (1 − wM )
p−

PR− = RRobs ×

(1 − wF )
,
(1 − wM )

where RRobs is the observed sex risk ratio if we ignore the
missing data. Similarly for PR+, the risk ratio between
females and males when all missing observations are set
to positive HIV status is

PR+ =

prF (1 − wF ) + wF
.
prM (1 − wM ) + wM

Now we derive the prevalence ratio inflation factor. We
show that true HIV prevalence ratio between females and
males (RRadj) can be expressed as


1 + wF (RF − 1)
.
RRadj = RRobs ×
1 + wM (RM − 1)

From (1) we know that the female HIV prevalence can be
written as
F F
pF = pnr
w + prF (1 − wF )

Dividing by prF on both sides yields
F
pF
pnr
=
wF + (1 − wF )
prF
prF
F /pF and rearranging terms, we get
Defining RF = pnr
r

pF
= 1 + wF (RF − 1),
pFr
which is equivalent to,


pF = prF 1 + wF (RF − 1) .
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The same calculations yield,


pM = prM 1 + wM (RM − 1)

If we define RRadj to be the population HIV prevalence
ratio comparing females to males, we get

RRadj



prF 1 + wF (RF − 1)
pF

= M = M
p
pr 1 + wM (RM − 1)

which is equivalent to our claim


1 + wF (RF − 1)
,
RRadj = RRobs ×
1 + wM (RM − 1)

where RRobs = prF /prM, the HIV prevalence ratio among
responders.
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